What is the recommended heparin dosing for an adult with acute coronary syndrome, including unfractionated and low‑molecular‑weight formulations and adjustments for renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Heparin Dosing for Acute Coronary Syndrome

For adults with ACS, use unfractionated heparin (UFH) with a loading dose of 60 IU/kg (maximum 4000 IU) followed by an infusion of 12 IU/kg/hour (maximum 1000 IU/hour), adjusted to maintain aPTT 60-80 seconds, or use enoxaparin 1 mg/kg subcutaneously every 12 hours with dose reduction to 1 mg/kg daily if creatinine clearance is below 30 mL/min. 1

Unfractionated Heparin (UFH) Dosing

Initial Medical Management

  • Loading dose: 60 IU/kg IV bolus (maximum 4000 IU)
  • Maintenance infusion: 12 IU/kg/hour (maximum 1000 IU/hour)
  • Target aPTT: 60-80 seconds 1
  • Monitor aPTT every 4 hours initially, then at appropriate intervals 2

For PCI Support

The dosing differs based on prior anticoagulation:

If already on anticoagulation:

  • Give additional UFH as needed to achieve ACT 250-300 seconds 1

If no prior anticoagulation:

  • 70-100 U/kg IV bolus to achieve target ACT 250-300 seconds 1, 3
  • Use 50-70 U/kg if GP IIb/IIIa inhibitors are planned 3

With Fibrinolytic Therapy

  • Same as initial medical management: 60 IU/kg bolus (max 4000 IU), then 12 IU/kg/hour infusion (max 1000 IU/hour) 1

Low-Molecular-Weight Heparin: Enoxaparin

Standard Dosing

  • 1 mg/kg subcutaneously every 12 hours 1

Renal Adjustment (Critical)

  • If CrCl <30 mL/min: Reduce to 1 mg/kg subcutaneously once daily 1
  • Use Cockcroft-Gault method to estimate creatinine clearance 4

For PCI Support

Timing of last enoxaparin dose determines additional dosing:

  • Last dose 8-12 hours ago OR only 1 dose given: 0.3 mg IV 1
  • Last dose within 8 hours: No additional dose needed 1
  • No prior anticoagulation: 0.5-0.75 mg/kg IV bolus 1

With Fibrinolytic Therapy

Age <75 years:

  • 30 mg IV bolus, then 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for first 2 doses) 1

Age ≥75 years:

  • No bolus; 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for first 2 doses) 1

Regardless of age, if CrCl <30 mL/min:

  • 1 mg/kg subcutaneously every 24 hours 1

Alternative Anticoagulants

Bivalirudin

  • 0.75 mg/kg IV bolus, then 1.75 mg/kg/hour infusion during PCI 1
  • Post-PCI for primary PCI: Continue 1.75 mg/kg/hour for 2-4 hours 1
  • Renal adjustment: If CrCl <30 mL/min, reduce infusion to 1 mg/kg/hour 1

Fondaparinux

  • 2.5 mg subcutaneously daily 1
  • With fibrinolytics: 2.5 mg IV, then 2.5 mg subcutaneously daily starting next day 1
  • Contraindicated if CrCl <30 mL/min 1
  • Do not use for PCI support due to catheter thrombosis risk 1

Critical Clinical Considerations

Monitoring Requirements

  • aPTT monitoring: Essential for UFH; target 1.5-2 times normal (60-80 seconds) 1, 2
  • Platelet counts: Monitor periodically throughout therapy regardless of route 2
  • Occult blood: Check stool periodically 2
  • Hematocrit: Monitor during therapy 2

Common Pitfalls to Avoid

Elderly and renal dysfunction patients are at highest bleeding risk 4, 5. Women and older patients have higher overdose risk with UFH, while younger men (<65 years) tend toward undertreatment 5.

Avoid crossover between enoxaparin and UFH during PCI procedures—this significantly increases bleeding complications 6.

Do not use fondaparinux to support PCI—the OASIS-5 trial showed increased catheter thrombus formation (0.9% vs 0.3% with enoxaparin) 1.

Renal Function Assessment

Calculate creatinine clearance using the Cockcroft-Gault equation, not MDRD or CKD-EPI, as dosing studies used this method 4. This is particularly important for enoxaparin dosing adjustments.

Duration of Therapy

Continue parenteral anticoagulation until revascularization is performed 1. Premature discontinuation causes rebound thrombin activity with greatest reinfarction risk in the first 4-8 hours 1.

Evidence Quality

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines 1 represent the most current and authoritative recommendations, superseding the 2021 ESC guidelines 3. The meta-analysis data shows UFH reduces MI or death (relative risk 0.67) compared to aspirin alone, though not statistically significant 1. Enoxaparin showed similar efficacy to UFH in multiple meta-analyses with no significant difference in death or MI (2.2% vs 2.3%) 1.

References

5
Research

The time has come for new, more precise guidelines in the treatment of high-risk acute coronary syndromes with heparin.

Circulation journal : official journal of the Japanese Circulation Society, 2008

6
Research

[Direct and indirect antithrombins in acute coronary syndromes].

Wiener klinische Wochenschrift, 2005

Related Questions

In the emergency department, when should unfractionated heparin (UFH) be preferred over low‑molecular‑weight heparin (LMWH) for patients with acute coronary syndrome (ACS)?
What is the appropriate unfractionated heparin dosing regimen during and after coronary artery stenting in an adult patient?
What is the recommended heparin dose for venous thromboembolism prophylaxis, including considerations for renal function, body weight, and bleeding risk?
Is heparin used in myocardial infarction (MI) and acute coronary syndrome (ACS)?
What is the recommended therapeutic regimen for full anticoagulation with low‑molecular‑weight heparin, including dosing, renal adjustments, and monitoring?
What specific data elements must a Medicare hospice physician include in the Continuity of Care (CTI) admission note for a patient with hypertensive heart disease?
In a child presenting with neck stiffness, photophobia, and altered consciousness after an upper respiratory tract infection, what findings would be expected on lumbar puncture?
In a 52-year-old woman with newly diagnosed high‑risk HER2‑positive (estrogen‑receptor‑negative) stage III breast cancer, which neoadjuvant regimen demonstrated the highest pathologic complete response rate in the DESTINY‑Breast11 phase III trial?
How should a patient presenting with a supraclavicular lymph node and a skin rash be evaluated and managed?
Can hydroxyzine be safely prescribed for a patient with an eating disorder, and what precautions such as baseline ECG, electrolyte monitoring, and dose adjustments are recommended?
Can sarcoidosis cause renal insufficiency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.